William A. Magioncalda

Will Magioncalda is a partner in the firm’s Business Law Department and a member of its Technology and Life Sciences groups.

Mr. Magioncalda represents clients across the life sciences and technology industries, which include global investment banks as well as public and private companies.

His work extends to every stage of the corporate life cycle from financing through successful initial public offering or acquisition, with a focus on public and private capital markets transactions such as IPOs, follow-on offerings and private placements of equity and debt securities. He also counsels clients on a wide array of corporate matters including mergers and acquisitions, securities law compliance, and corporate governance.

A selection of Mr. Magioncalda’s recent representations include:

Initial Public Offerings and Follow-on Offerings

• The underwriters in Royalty Pharma plc’s $2.5 billion initial public offering and $728 million secondary follow-on offering
• Moderna, Inc. in its $1.34 billion and $500 million public follow-on offerings
• The underwriters in Exscientia’s $350.4 million initial public offering and concurrent $160 million private placements
• The underwriters in Sarepta Therapeutics’ $575 million public follow-on offering
• The underwriters in Krystal Biotech’s $200 million and $125 million public follow-on offerings
• The underwriters in Omega Therapeutic’s $144.6 million initial public offering
• The underwriters in Ambrx Biopharma’s $126 million initial public offering
• The underwriters in Valneva SE’s $107.6 million initial public offering and $102 million public follow-on offering
• Codiak BioSciences in its $82.5 million initial public offering and $66.4 million public follow-on offering
• HOOKIPA Pharma, Inc. in its $84 million initial public offering
• The underwriters in Repare Therapeutics, Inc.’s $253 million initial public offering and $101.2 million public follow-on offering
• The underwriters in Harmony Biosciences’ $147.6 million initial public offering
• The underwriters in Pandion Therapeutics’ $135 million initial public offering
• Goldman Sachs & Co. and other underwriters in Arvinas, Inc.’s $120 million initial public offering and $150 million and $400 million public follow-on offerings
• The underwriters in Immunomedics, Inc.’s $420 million and $285 million public follow-on offerings

Other Corporate Transactions

• GameChange Solar in its $150 million preferred stock financing 
• The initial purchasers in Royalty Pharma’s $6 billion and $1.3 billion offerings of its convertible senior notes
• Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
• The initial purchasers in Dynavax Technologies’ $200 million offering of its convertible senior notes
• Galecto in its $50 million “at-the-market” offering
• Cowen as sales agent in multiple ATM facilities, including for Albireo Pharma, Ovid Therapeutics, Syndax Pharmaceuticals and Dynavax Technologies
• Akili Interactive Labs, Inc. in its $55 million Series C financing
• Even Financial, Inc. in its $25 million Series B financing and $18 million Series A financing
• Aircall.io, Inc. in its $29 million Series B financing

Prior to joining Goodwin, Mr. Magioncalda was an associate at Cravath, Swaine & Moore LLP in New York.